FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis

The FDA expanded UPLIZNA's label to include treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR+) or anti-muscle-specific tyrosine kinase (MuSK+) antibody positive, based on Phase 3 MINT results showing strong efficacy at 26 weeks and continued improvement through 52 weeks in AChR+ patients. The approval is UPLIZNA's third indication and makes it the first and only CD19-targeted B‑cell therapy for anti‑AChR and anti‑MuSK antibody‑positive gMG—notable given that ~85% of MG patients have the generalized form and roughly 85% are AChR+ (≈7% MuSK+). UPLIZNA generated $379 million in 2024 sales and $422 million in the first nine months of 2025, and the label expansion should broaden the drug’s addressable market and support further revenue upside for Amgen.

Analysis

Amgen announced an FDA label expansion for UPLIZNA to treat adults with generalized myasthenia gravis (gMG) who are AChR+ or MuSK+ based on Phase 3 MINT results showing strong efficacy at 26 weeks and continued improvement through 52 weeks in AChR+ patients. The approval is UPLIZNA's third indication and establishes it as the first and only CD19-targeted B‑cell therapy for these antibody‑positive gMG populations. Sales momentum is visible in the release: UPLIZNA generated $379 million in 2024 and $422 million in the first nine months of 2025, and AMGN shares were modestly up 0.63% on the most recent close. The label expansion matters because ~85% of myasthenia gravis patients have the generalized form and antibody prevalence is high for AChR (~85%) and lower for MuSK (~7%), which suggests a meaningful addressable population increase but uneven evidence maturity between subgroups. Key near‑term risks to commercial upside include payer coverage, real‑world adoption, diagnostic testing rates for antibody status, and whether MuSK+ durability beyond 26 weeks replicates the AChR+ 52‑week improvement.

Key Decisions for Investors

• Consider modestly overweighting AMGN to capture potential upside from UPLIZNA's label expansion given accelerating sales ($379m in 2024 vs $422m in the first nine months of 2025),
• Monitor near‑term indicators including quarterly UPLIZNA revenue, payer coverage decisions, rates of antibody testing (AChR/MuSK) and real‑world durability data—particularly for MuSK+ patients where longer‑term benefit is less established,
• If commercial or reimbursement uncertainty is a concern, limit position size or use hedges until consistent post‑approval uptake and payer access evidence emerges